Table 3.
Adjusted change in general self-efficacy and patient activation measure score in participants of the TELEmedicine for inflammatory bowel disease (TELE-IBD) trial
| Variable | Adjusted estimate change in GSE (ß coeff, SE) | p value | Adjusted estimate change in PAM (ß coeff, SE) | p value |
|---|---|---|---|---|
| Arm | ||||
| Standard | 0.56, 0.61 | 0.36 | Ref | |
| EOW | −0.01, 0.61 | 0.98 | −3.96, 2.59 | 0.13 |
| Weekly | Ref | 1.94, 2.68 | 0.47 | |
| LOC | ||||
| 0–10 | Ref | Ref | ||
| 11–21 | 0.64, 0.51 | 0.22 | 1.36, 2.25 | 0.55 |
| Baseline GSE | ||||
| 10–30 | 1.83, 0.55 | 0.001 | Ref | |
| 31–40 | Ref | 5.25, 2.43 | 0.03 | |
| Baseline PAM | ||||
| Level 1 | 1.51, 1.49 | 0.31 | 31.3, 5.97 | <0.001 |
| Level 2 | 0.19, 1.35 | 0.89 | 18.6, 3.63 | <0.001 |
| Level 3 | 0.53, 1.36 | 0.70 | 7.1, 2.51 | 0.005 |
| Level 4 | Ref | Ref | ||